Abstract
Integrins are large, heterodimeric surface molecules of wide importance in cell adhesion. The N-terminal half of all integrin α-subunits contains seven weak sequence repeats of ≈60 amino acids that are important in ligand binding and have been predicted to fold cooperatively into a single β-propeller domain with seven β-sheets. We provide evidence supporting this model with a mouse mAb to human Mac-1 (αMβ2, CD11b/CD18). This antibody, CBRM1/20, binds to amino acid residues that are in different repeats and are 94 residues apart in the primary structure in the loop between strands 1 and 2 of β-sheet 5 and in the loop between strands 3 and 4 of β-sheet 6. The 1–2 loops of β-sheets 5–7 in integrins have EF hand-like Ca2+-binding motifs. CBRM1/20 binds to Mac-1 in the presence of Ca2+ or Sr2+ with an EC50 of 0.2 mM. Mg2+ or Mn2+ cannot substitute. Antibodies to other epitopes on the Mac-1 β-propeller domain bind in the absence of calcium. mAb CBRM1/20 does not block ligand binding. Thus, the region on the lower surface of the β-propeller domain to which mAb CBRM1/20 binds does not bind ligand and, furthermore, cannot bind other integrin domains, such as those of the β-subunit.
Found on almost all cells of multicellular organisms, integrins play a pivotal role in cellular adhesion. They are large, heterodimeric surface receptors generally comprised of an α-subunit of ≈1,000 and a β-subunit of ≈800 amino acids (1, 2). The N-terminal half of the α-chain consists of seven repeats with weak homology to one another denoted Phe-Gly, Gly-Ala-Pro (FG-GAP) repeats (3); the three or four most C-terminal repeats contain a putative cation binding motif (4). The repeats are interrupted in some integrins by insertion of a domain of ≈200 residues called the “I” domain.
Several regions within the integrin α- and β-subunits, mainly in their N-terminal halves, have been implicated in ligand binding. As a rule, ligand binding to integrins depends on the presence of divalent cations (5). I domains, when present, have been demonstrated to play an important role in ligand binding (6–8). Integrin-mediated adhesion is regulated tightly by complex and little-understood mechanisms that involve both the intra- and extracellular domains (2, 9–12).
Structural knowledge on integrins is limited. Isolated I domains have been expressed in bacteria, and their crystal structures have been solved (13, 14). No atomic level insight has been obtained for other domains. However, it has been predicted that the seven N-terminal FG-GAP repeats fold into a β-propeller, a toroidal all β-structure (3). Previously, the repeats were thought of as independently folded domains, but in this model, they fold into a single, compact domain. Seven β-sheets, each called a W and containing four antiparallel β-strands, are ordered around a pseudosymmetry axis like blades in a propeller (15) (Fig. 1). β-propellers are known from several proteins, including the β-subunit of the heterotrimeric G protein transducin (16) and galactose oxidase (17).
Putative Ca2+ binding motifs are present in integrins that are similar to those in EF hands (4). Ca2+ has been reported to bind to integrins, including αIIbβ3 (18, 19), but whether the binding sites correspond to the cation-binding motifs is not known. Removal of Ca2+ from αIIbβ3 can induce subunit dissociation and inhibit ligand binding (18). On the other hand, the combined absence of Ca2+ and presence of Mg2+ can stimulate ligand binding by other integrins (20, 21). The β-propeller model predicts that the Ca2+ binding motifs are close to one another (on the lower surface of the β-propeller in the loops connecting β-strands 1 and 2) in W5, W6, and W7 (Fig. 1). A possible direct role in ligand binding for the Ca2+ bound to these motifs has been proposed often. The effect of Ca2+ on the conformation of the β-propeller domain is unknown.
To test the β-propeller fold, we sought a mAb to an epitope that would contain residues that were distant in the amino acid sequence and thus would place constraints on the fold. Here, we describe such a mAb to Mac-1 (αMβ2, CD11b/CD18), an integrin on leukocytes that binds ligands including intercellular adhesion molecule-1, iC3b, and fibrinogen (22). The mAb recognizes residues in the 1–2 loop of W5 containing a Ca2+-binding motif and the 3–4 loop of W6 of the Mac-1 α-subunit. Of interest, the mAb requires Ca2+ for binding to Mac-1. Furthermore, its footprint is predicted to include a substantial portion of the bottom of the β-propeller domain, yet it does not block ligand binding by Mac-1 or affect α- and β-subunit association.
MATERIALS AND METHODS
DNA Constructs and Mutagenesis.
The majority of the coding sequence of the human αM subunit cDNA, nucleotides 73–3534 (23), was excised by full and partial digestion with XbaI and XmaI, respectively, and was cloned into the XbaI site of pCDNA3.1+ (Invitrogen) by using a linker that reconstructed the remaining 14 coding nucleotides and provided a stop codon and a XbaI site. PCR primers were synthesized that allowed ligation into the NotI/SacI sites of pBluescript II (Stratagene) and allowed amplification of Mac-1 cDNA fragments that included the NotI site in the linker 5′ to the coding region and the BspEI site at amino acid residue 180 or included the BspEI–BbsI fragment from residue 180 to 672. Mutagenesis of these fragments was done by inverse PCR (24). In brief, a pBluescript II plasmid containing one of the cDNA fragments was amplified by using two mutated primers (GIBCO/BRL), and the linear product was circularized after digestion with a class 2s restriction enzyme, BsaI. The mutated cDNA fragments were excised from purified plasmid with NotI and BspEI or BspEI and BbsI and swapped into the wild-type construct. Human β2 cDNA was excised from CDM8 (25) with XbaI and cloned into the XbaI site of pCDNA3.1+. PCRs were performed with Pfu DNA polymerase (Stratagene), and the constructs were verified by sequence analysis. Plasmid DNA for transfection was prepared by QIAprep Spin Kit or Maxi Kit (Qiagen, Chatsworth, CA).
Tissue Culture, Transfection, and Cell Preparation.
COS-7 cells grown in 10-cm tissue culture dishes in RPMI 1640 medium supplemented with 10% fetal bovine serum (JRH Biosciences, Lenexa, KS) and gentamicin (GIBCO/BRL) were cotransfected by using DEAE dextran with 10 μg of α-subunit and 2.5 μg of β-subunit cDNA (26). Transfected cells were replated after treatment with trypsin–EDTA 48 h after transfection and were detached 24 h later with 5 mM EDTA. Approximately 40% expressed Mac-1 as shown by flow cytometry. Human neutrophils were isolated from the whole blood of healthy volunteers by dextran sedimentation, Histopaque 1077 (Sigma) gradient centrifugation at room temperature, and hypotonic lysis at 4°C (27). To vary the divalent cation concentration, the purified neutrophils were washed twice in HE buffer [10 mM Hepes/137 mM NaCl/2.7 mM KCl, pH 7.4/0.2% human serum albumin (Calbiochem)] containing 4 mM EDTA, then twice in HE buffer, and finally twice in HE buffer supplemented as indicated with 2 mM EDTA or EGTA and/or with the indicated concentrations of cations. In immunofluorescent labeling, the same buffer was used for washes and dilution of primary antibodies and fluorescein isothiocyanate goat anti-mouse IgG.
mAb Binding.
Mac-1 α-chain-specific mAbs were CBRM1/10, CBRM1/20, CBRM1/29, CBRM1/30, and CBRM1/32 (28) and CBRN1/6 and CBRN3/4 (Na, S. and T.A.S., unpublished data). The myeloma IgG1 control was X63 (American Type Culture Collection). Purified CBRM1/20 IgG was diluted from a 1 mg/ml stock in PBS to 5 μg/ml. Other antibodies were diluted 1 to 200 from ascites. Cells were incubated for 40 min in 96-well plates with each mAb and then, after washing twice, with fluorescein isothiocyanate goat anti-mouse IgG (Zymed) diluted 1 to 50 for 30 min followed by three washes. Neutrophils were washed and incubated in buffers described above, and COS-7 cells were washed and incubated in L-15 medium (Sigma) at 4°C. Cells were fixed in buffer with 1% formaldehyde before flow cytometry for measurement of fluorescence intensity. At least 2,500 cells were acquired on a FACScan instrument (Becton Dickinson).
Molecular Modeling and Sequence Comparison.
Modeling was done with segmod (29) of look, version 2.0.5 (Molecular Applications Group, Palo Alto, CA) and modeller Release 4 (http://guitar.rockefeller.edu/modeller) (30). Templates were 1 tbg, 1 gof, and 2 gbp (http://www.pdb.bnl.gov). The packing quality of the models was evaluated with quachk of what if (http://www.sander.embl-heidelberg.de/whatif/) (31).
RESULTS
A Discontinuous Epitope in the β-Propeller Domain.
To test the β-propeller model, we searched for a mouse mAb to human Mac-1 (αMβ2) that would recognize an epitope containing residues from different FG-GAP repeats. Initially, 28 different Mac-1α subunit chimeras were constructed. In each chimera, 1 of the 28 predicted loops in the β-propeller model contained murine instead of human sequence. mAbs were tested for reactivity with the α-subunit chimeras coexpressed with the human β-subunit in COS cells. Binding of mAb CBRM1/20 was abolished by two different mutations: hu(W5L1–2)mo, in which the 1–2 loop of W5 was substituted, and hu(W6L3–4)mo, in which the 3–4 loop of W6 was substituted (Table 1). These loops are almost 100 residues apart in the primary structure (Fig. 1). Substitution of the 26 other loops with murine sequence had no effect on mAb CBRM1/20 binding but did allow localization of mAbs CBRM1/32, CBRN1/6, and CBRN3/4 to individual loops in the predicted β-propeller domain (data not shown). The mutations that abrogated CBRM1/20 binding had no effect on binding of these three other β-propeller mAbs, the mAb CBRM1/29 to the I domain (Table 1), or mAbs CBRM1/10 or CBRM1/30 to the C-terminal region (data not shown).
Table 1.
Mutation | CBRM 1/20 | CBRM 1/32 | CBRN 1/6 | CBRN 3/4 | CBRM 1/29 |
---|---|---|---|---|---|
Binding (% of human wild-type ± SD) | |||||
hu(W5L1-2)mo | 0 ± 1 | 103 ± 9 | 101 ± 11 | 103 ± 12 | 104 ± 3 |
V450M | 0 ± 2 | 87 ± 1 | 97 ± 2 | 86 ± 11 | 103 ± 4 |
S452A | 107 ± 4 | 99 ± 5 | 93 ± 10 | 100 ± 2 | 91 ± 4 |
N453D | 5 ± 3 | 101 ± 1 | 96 ± 2 | 99 ± 14 | 106 ± 0 |
S455N | 93 ± 3 | 113 ± 8 | 108 ± 5 | 109 ± 12 | 107 ± 8 |
D457N | 14 ± 4 | 70 ± 7 | 72 ± 11 | 71 ± 7 | 61 ± 7 |
hu(W6L3-4)mo | 1 ± 1 | 104 ± 5 | 111 ± 6 | 106 ± 8 | 111 ± 3 |
H541Y | 96 ± 12 | 97 ± 2 | 97 ± 9 | 106 ± 24 | 97 ± 4 |
T543A | 104 ± 5 | 95 ± 2 | 100 ± 4 | 94 ± 0 | 90 ± 15 |
G545I | 51 ± 1 | 95 ± 5 | 90 ± 1 | 95 ± 12 | 99 ± 5 |
S546A | 92 ± 1 | 100 ± 1 | 98 ± 1 | 98 ± 2 | 100 ± 7 |
G547S | 0 ± 1 | 92 ± 0 | 102 ± 14 | 84 ± 8 | 91 ± 1 |
I548L | 108 ± 1 | 106 ± 7 | 93 ± 9 | 105 ± 2 | 106 ± 0 |
P550A | 122 ± 6 | 97 ± 4 | 100 ± 18 | 83 ± 21 | 90 ± 16 |
Q554H | 92 ± 1 | 102 ± 24 | 104 ± 14 | 116 ± 11 | 94 ± 19 |
COS-7 cells were cotransfected transiently with cDNAs for the mutated or wild-type Mac-1 α-subunit and human β2-subunit. Cells were stained with mAbs, and fluorescein isothiocyanate anti-IgG in L15 medium, which contains 1.26 mM Ca2+ and the % positive cells relative to wild-type, was determined after subtracting staining with X63 myeloma IgG.
The epitope recognized by mAb CBRM1/20 was localized further with single human-to-mouse amino acid substitutions (Table 1). Three of these substitutions in the 1–2 loop of W5, all in the EF hand-like Ca2+-binding motif, abolished or decreased binding of CBRM1/20 (Table 1). Of these, D457N was expressed on the surface at a level lower than the wild type, as shown with the other mAbs (Table 1). However, binding of mAb CBRM1/20 was decreased much more than binding of other mAbs and therefore appeared to be affected specifically. In the 3–4 loop of W6, the substitution of Gly 547 to Ser abolished binding of mAb CBRM1/20 completely. The substitution Gly 545 to Ile consistently decreased binding to 50% of the wild type.
Model of the Mac-1 β-Propeller Domain.
A model of the predicted β-propeller domain of Mac-1 was built by using segmod (29) of look and an alignment (3) with the β-propeller domain of the β-subunit of the G protein transducin (G β) (16). The loops in integrins are longer than in G β (3), and the 3–4 loop in W5 of the galactose oxidase β-propeller domain (17) was used as the template for the longer 3–4 loops of W5–7 in integrins.
The Ca2+-binding motifs in the 1–2 loops of W5–7 in integrins were the most challenging modeling problem. Whereas in the integrin β-propeller model the Ca2+-binding motif occurs in a hairpin turn between β-strands, in the EF hand motif, the Ca2+-binding site occurs in the loop between two α-helices (32). In the EF hand motif, the residues that coordinate Ca2+ directly or through a water molecule are in positions 1, 3, 5, 7, 9, and 12 of a 12-residue consensus sequence. A similar sequence motif and structure for residues 1–9 is found in galactose binding protein (GBP); however, the loop is between an α-helix and a β-strand, and the sixth coordination is from a glutamic acid residue that is distal in the sequence but in an adjacent, parallel β-strand. However, the GBP Ca2+ binding site as a whole adopts a conformation very similar to the EF hand sites (33). Among different EF hands and GBP, the structurally most conserved region is residues 1–6 (32). By using this six-residue region as a structural template (Fig. 2) but with no restraints on its orientation relative to the β-propeller domain and by placing 2.4 ± 0.1 Å restraints on the distances between Ca2+ and putative oxygen ligands in EF hand motif positions 1, 3, 5, 7, and 9, modeller (30) was used to build the 1–2 loops into the look model (Figs. 2 and 3). The average packing quality for the final model was −1.62 as evaluated with quachk of whatif. For comparison, “a molecule is certain to be incorrect if the score is below −3.0. Poorly refined molecules, very well energy minimized misthreaded molecules and low homology models give values between −2.0 and −3.0. The average quality of 200 highly refined Xray structures was −0.5+/−0.4” (31).
The Spatial Proximity of Residues in the CBRM1/20 Epitope in the β-Propeller Model.
The 1–2 and 3–4 loops in β-propellers are the loops that form the lower surface (Fig. 1). In G β and galactose oxidase, the 1–2 loops of each W are in contact with the 3–4 loops of the following W but not the preceding W, thus predicting the contact between the 1–2 loop of W5 and the 3–4 loop of W6, which bear the CBRM1/20 epitope. These loops are longer in integrins than in G β, decreasing prediction accuracy, but indeed are predicted to be in close proximity (Fig. 3). In the model, the three antigenic residues in the 1–2 loop of W5 are 15.8 ± 4.2 Å from the two antigenic residues in the 3–4 loop of W6, based on their Cα atom positions.
Metal Ion Dependence of CBRM1/20 Binding.
Cation requirements for binding of mAb CBRM1/20 were investigated by using flow cytometry. CBRM1/20 binding to Mac-1 on purified neutrophils required Ca2+, and Ca2+ titration showed that half-maximal binding of mAb CBRM1/20 was obtained at a concentration of 0.2 mM (Fig. 4). Binding of three other mAbs that were mapped to the β-propeller domain was identical in the absence and presence of divalent cations (Fig. 4). Sr2+ supported CBRM1/20 mAb binding as well as calcium. Ba2+ supported binding markedly less well than Ca2+ or Sr2+. In 2 mM EDTA, or in 1 mM Mg2+ or 1 mM Mn2+, binding was abolished completely (data not shown).
The mutants N453D, D457N, and G545I that showed decreased rather than abolished CBRM1/20 binding were incubated with CBRM1/20 in the presence 10 mM Ca2+. Binding of antibody was identical to that in the physiological buffer with 1.26 mM Ca2+ used above (data not shown). Hence, the decreased antibody binding of these mutants is not due to a lowered affinity for calcium.
DISCUSSION
We have found that a Ca2+-dependent epitope on integrin Mac-1 recognized by the mAb CBRM1/20 includes residues 94 positions apart in the amino acid sequence of the α-chain. The residues are in different FG-GAP repeats, and if these folded as separate domains, they would be expected to be separated widely. However, the β-propeller model predicts that these residues are present in loops that are adjacent in the three-dimensional structure. They are 15.8 ± 4.2 Å apart in the model and thus could fit easily within an antibody epitope ≈30 Å in diameter. The residues that are most energetically important for protein–protein interactions are in a “hotspot” near the center of the interface (34), and the observed distances would allow both loops to be present in the central region of an epitope. Our results are highly consistent with the predicted β-propeller fold. An alternate model has been proposed for FG-GAP repeats 5 and 6 of the integrin lymphocyte function-associated antigen-1 based on the α-helical EF hand modules of calmodulin (35). In this model, the loops bearing the antigenic residues are on opposite sides of the protein, and the antigenic residues are 37.7 ± 3.7 Å apart, as determined from a model made with look based on the published alignment (35). Our data, therefore, can rule out this model, which also is not supported by secondary structure or threading predictions (3). However, the question may be asked whether other folds also could be consistent with the experimental data. To address this question, the probability of finding residues on the surface of proteins within ≤15.8 Å of one another by chance alone was calculated. All proteins in the Protein Data Bank (Upton, NY) that are <30% identical in sequence with one another and have polypeptide chains of >200 residues were used. This database contained 456 chains and was representative of all fold classes. The distance between all residues i and j that are 85 to 105 sequence positions apart and on the protein surface as shown by >20% solvent accessibility or both on the surface and in loops was calculated. The average distance also was calculated from residues i, i + 3, and i + 7 to residues j and j + 2, where j to i ranged from 85 to 105. This relationship mimics that between the five residues in the antigenic determinant for CBRM1/20 mAb. By using these four different distance distributions calculated by A. Sali and A. Badretdinov (Rockefeller University, New York), the probability of finding residues ≤16.5 Å apart by chance alone was found to range from 5.5 to 6.5%. Almost identical distributions were obtained with proteins in which loops are grouped together on opposite ends of the protein, as in the integrin I domain. We conclude that the β-propeller domain fits the experimental data significantly better than random domains, with P ≈ 0.06.
The evidence that recognition of human Mac-1 by mAb CBRM1/20 depends on Ca2+ and is abolished or decreased by three different human-to-mouse substitutions that are within a cation-binding motif in the 1–2 loop of W5 suggests that this mAb acts as a probe of Ca2+ binding to this loop. The EC50 for Ca2+ is 0.2 mM. The Kd for Ca2+ may differ if mAb binding alters the affinity of the site for Ca2+ but should approximate the observed EC50. The importance of Ca2+ in maintenance of α/β-subunit association, in modulating ligand binding, and in regulating exposure of activation epitopes has received wide support (18, 20, 21, 36). In these types of assays, Ca2+ is effective in the 0.1–1 mM range, in excellent agreement with our results. Direct measurement of Ca2+ binding to low affinity sites in proteins is technically difficult; published measurements of calcium binding to integrins or integrin fragments yield Kd values that vary >1,000-fold, from μM to mM (19, 37–39).
There are important similarities and differences between EF hand and integrin Ca2+-binding motifs (Table 2). The Asp in position 1 is almost invariant in both motifs; its two side chain oxygens set up the turn in the EF hand loop, with one coordinating Ca2+ and the other accepting a hydrogen bond from the mainchain NH of the residue in position 6 (32). The Gly in position 6 of the EF hand motif promotes a 90° turn in the chain. It is in a position of the Ramachandran plot common for Gly but not other residues; Gly is less abundant in this position in integrins. The primary structure of the integrin calcium binding site deviates further in several ways. In the integrins, position 5 is always Asp or Asn, in contrast to the EF hands, where other residues also occur. Furthermore, the obligate hydrophobic residues in position 8 of the EF hand are not conserved in the integrins. Except for basic residues, almost any residue is found in this position in integrins and is often charged or polar and is rarely hydrophobic. Finally, the integrin loop has a highly conserved Asp in position 9, in contrast to the EF hand, where several different residues are found (Table 2). The deviations from the EF hand motif, especially in positions 5, 6, 8, and 9, suggest a variant mode of coordination. In particular, the constraints on a turn between adjacent β-strands make it likely that the position of the residue in position 9 differs, correlating with the preference for Asp in integrins but not in EF hands. Our model suggests that this residue in integrins may have a coordination position more similar to that of the Glu in position 12 of EF hands. As to the one “missing” coordination position in integrins, we can find no conserved, acidic residue distant in sequence but close in the model structure, analogous to that in GBP. The Kd for calcium measured here is higher than in EF hands and GBP (10−5 to 10−9 M), possibly reflecting the lack of a 12th coordination position. EF hands and GBP prefer Ca2+ over Sr2+ by ≈103 and Ca2+ over Ba2+ by >105 (40), indicating a constraining force acting against expansion of the cavity to accommodate the increasing ionic radii of Sr2+ and Ba2+. The lack of preference between Ca2+ and Sr2+ of the integrin Ca2+ binding site as probed by mAb CBRM1/20 suggests that the protein ligands do not encapsulate completely the ion (40), which again is consistent with at least one coordination site being exposed to solvent.
Table 2.
Residue or residue group | Sequence Position
|
||||||||
---|---|---|---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | |
% abundance in integrins, % abundance in EF hands | |||||||||
D | 97, 99 | 0, 0 | 41, 76 | 3, 2 | 79, 47 | 5, 1 | 0, 1 | 8, 0 | 96, 34 |
N | 0, 0 | 0, 1 | 48, 22 | 9, 8 | 21, 24 | 1, 2 | 2, 1 | 13, 0 | 1, 4 |
E | 3, 0 | 0, 7 | 1, 0 | 4, 2 | 0, 1 | 0, 0 | 3, 7 | 9, 0 | 3, 13 |
Q | 0, 0 | 0, 11 | 0, 0 | 18, 5 | 0, 0 | 0, 1 | 1, 4 | 9, 0 | 0, 2 |
ST | 0, 0 | 0, 16 | 9, 1 | 5, 3 | 0, 29 | 14, 0 | 8, 30 | 23, 0 | 0, 34 |
G | 0, 0 | 0, 0 | 1, 0 | 34, 53 | 0, 0 | 68, 93 | 0, 0 | 1, 0 | 0, 12 |
AVLICM | 0, 0 | 91, 26 | 0, 1 | 12, 1 | 0, 0 | 2, 1 | 30, 12 | 15, 100 | 0, 1 |
P | 0, 0 | 0, 0 | 0, 0 | 0, 0 | 0, 0 | 0, 0 | 0, 0 | 23, 0 | 0, 0 |
FYW | 0, 0 | 9, 2 | 0, 0 | 0, 0 | 0, 0 | 1, 0 | 54, 27 | 0, 0 | 0, 0 |
HRK | 0, 0 | 0, 36 | 0, 0 | 15, 26 | 0, 0 | 9, 2 | 3, 19 | 1,0 | 0, 0 |
Residues in the calcium binding sites (a total of 117) from all available integrin sequences were counted. The EF hand sequences were taken from ref. 45. Only eucaryotic EF hand sequences with observed or inferred calcium binding that had no insertion or deletion (a total of 498 calcium binding sequences) were analyzed. The residues are given by one-letter code.
The loss of antigenicity after the N453D and D457N mutations is most interesting because these residues occupy positions 5 and 9 in the Ca2+ binding motif and their sidechain oxygen atoms are predicted to ligate Ca2+. Their backbone, not sidechain atoms, are predicted to be exposed to antibody. We predict that the change between acidic and amide sidechain alters ligation or hydrogen bonding around the Ca2+, resulting in a change in backbone conformation that is detected by the antibody. It is striking that, of 117 integrin calcium binding motifs surveyed (Table 2), W5 of murine Mac-1 is the only one with an Asn in position 9. The Asp in position 5 of that loop may compensate for the lack of the acidic residue in position 9. The consistently poorer expression seen after mutation of the Asp453 to Asn but not after mutation of Asn457 to Asp suggests that at least one of the two residues in positions 5 and 9 may have to be an Asp for proper expression.
We have localized the mAb CBRM1/32 to the 2–3 loop of W6 and the mAbs CBRN1/6 and CBRN3/4 to the 3–4 loop of W4 of Mac-1 (Lu, C., C.O., and T.A.S., unpublished data). Binding of these antibodies is unaffected by removal of Ca2+. Therefore, conformational changes induced by removal of calcium are limited to specific regions of the β-propeller domain. It has been proposed widely that the Ca2+ binding motifs of integrins play a direct role in ligand binding by integrins. Our localization of the CBRM1/20 binding site to the Ca2+ binding motif in W5 rules out a direct role for this site in ligand binding by Mac-1 because mAb CBRM1/20 does not inhibit binding to four different ligands (6). The β-propeller model suggested that the upper rather than lower face of this domain is involved in ligand recognition (3). This view received further support from analysis of the interaction between the non-I domain containing integrin α4β1 and vascular cell adhesion molecule 1 (41).
The area on the lower surface of the β-propeller domain bound by mAb CBRM1/20 (Fig. 3) cannot be occupied at the same time by other integrin domains or subunits, creating important implications for whether the central cavity in the β-propeller is filled. All seven- and eight-bladed β-propellers except G β have a central cavity along the pseudosymmetry axis that is filled with a prosthetic group or, in the case of galactose oxidase, with a polypeptide finger extending from another domain (3, 16, 17). The central cavity in G β, which appears to be the closest structural homologue of the integrin β-propeller, contains only solvent. Strand 1 and the 1–2 loop of W5 form one side of this channel. Although the domain from which the polypeptide finger extends into the central cavity in galactose oxidase contains only 100 residues, it binds to all seven 1–2 loops as shown by burial of solvent-accessible surface on at least 2 and an average of 3.1 residues in each loop. An analogous domain in integrins would make a 1–2 loop less accessible in an antibody epitope. We therefore believe that it is more likely that the central cavity will be free, as it is in G β. In the absence of a coordinating residue in the polypeptide finger, it would be unlikely that a divalent cation could be ligated in the central cavity, as might have been conceived by analogy to galactose oxidase (3). Thus, our data on mAb epitopes not only supports the β-propeller domain hypothesis but also is beginning to provide hints, by a process of elimination, of where interfaces with other domains may lie. It appears that the β-propeller domain in the integrin α-subunit has important interactions with the integrin β-subunit because mAbs that bind to four different epitopes on the Mac-1 β-propeller domain, including CBRM1/20, do not react in the absence of the β-subunit (Lu, C., C.O., and T.A.S., unpublished data). Similar results have been obtained with lymphocyte function-associated antigen-1 (42). Our results interpreted in light of the β-propeller model make it unlikely that the Ca2+ in the 1–2 loop of W5 could ligate the β-subunit and suggest that an indirect role for Ca2+ in stabilizing association between the α- and β-subunits should be given serious consideration.
Acknowledgments
We thank Andrej Sali, Azat Badretdinov, and Roberto Sánchez for help with modeller. We thank Martin Hemler and Michael N. G. James for refereeing the manuscript. C.O. was supported by a fellowship from The Danish Natural Science Research Council. This work was supported by National Institutes of Health Grant CA31799.
ABBREVIATION
- GBP
galactose binding protein
- FG-GAP
Phe-Gly, Gly-Ala-Pro
Footnotes
Data deposition: The atomic coordinates for the Mac-1α β-propeller domain model have been deposited in the Protein Data Bank, Biology Department, Brookhaven National Laboratory, Upton, NY 11973 (reference 1A8X).
References
- 1.Springer T A. Nature (London) 1990;346:425–433. doi: 10.1038/346425a0. [DOI] [PubMed] [Google Scholar]
- 2.Hynes R O. Cell. 1992;69:11–25. doi: 10.1016/0092-8674(92)90115-s. [DOI] [PubMed] [Google Scholar]
- 3.Springer T A. Proc Natl Acad Sci USA. 1997;94:65–72. doi: 10.1073/pnas.94.1.65. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Tuckwell D S, Brass A, Humphries M J. Biochem J. 1992;285:325–331. doi: 10.1042/bj2850325. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Loftus J C, Smith J W, Ginsberg M H. J Biol Chem. 1994;269:25235–25238. [PubMed] [Google Scholar]
- 6.Diamond M S, Garcia–Aguilar J, Bickford J K, Corbi A L, Springer T A. J Cell Biol. 1993;120:1031–1043. doi: 10.1083/jcb.120.4.1031. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Michishita M, Videm V, Arnaout M A. Cell. 1993;72:857–867. doi: 10.1016/0092-8674(93)90575-b. [DOI] [PubMed] [Google Scholar]
- 8.Huang C, Springer T A. J Biol Chem. 1995;270:19008–19016. doi: 10.1074/jbc.270.32.19008. [DOI] [PubMed] [Google Scholar]
- 9.Springer T A. Cell. 1994;76:301–314. doi: 10.1016/0092-8674(94)90337-9. [DOI] [PubMed] [Google Scholar]
- 10.Diamond M S, Springer T A. Curr Biol. 1994;4:506–517. doi: 10.1016/s0960-9822(00)00111-1. [DOI] [PubMed] [Google Scholar]
- 11.Ginsberg M H. Biochem Soc Trans. 1995;23:439–446. doi: 10.1042/bst0230439. [DOI] [PubMed] [Google Scholar]
- 12.Loftus J C, Liddington R C. J Clin Invest. 1997;99:2302–2306. doi: 10.1172/JCI119408. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Lee J-O, Rieu P, Arnaout M A, Liddington R. Cell. 1995;80:631–638. doi: 10.1016/0092-8674(95)90517-0. [DOI] [PubMed] [Google Scholar]
- 14.Qu A, Leahy D J. Proc Natl Acad Sci USA. 1995;92:10277–10281. doi: 10.1073/pnas.92.22.10277. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Murzin A G. Proteins. 1992;14:191–201. doi: 10.1002/prot.340140206. [DOI] [PubMed] [Google Scholar]
- 16.Sondek J, Bohm A, Lambright D G, Hamm H E, Sigler P B. Nature (London) 1996;379:369–374. doi: 10.1038/379369a0. [DOI] [PubMed] [Google Scholar]
- 17.Ito N, Phillips S E V, Stevens C, Ogel Z B, McPherson M J, Keen J N, Yadav K D S, Knowles P F. Nature (London) 1991;350:87–90. doi: 10.1038/350087a0. [DOI] [PubMed] [Google Scholar]
- 18.Jennings L K, Phillips D R. J Biol Chem. 1982;257:10458–10466. [PubMed] [Google Scholar]
- 19.Rivas G A, Gonzalez–Rodriguez J. Biochem J. 1991;276:35–40. doi: 10.1042/bj2760035. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Hu D D, Barbas C F, III, Smith J W. J Biol Chem. 1996;271:21745–21751. doi: 10.1074/jbc.271.36.21745. [DOI] [PubMed] [Google Scholar]
- 21.Dransfield I, Cabañas C, Craig A, Hogg N. J Cell Biol. 1992;116:219–226. doi: 10.1083/jcb.116.1.219. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Hemler M E. Annu Rev Immunol. 1990;8:365–400. doi: 10.1146/annurev.iy.08.040190.002053. [DOI] [PubMed] [Google Scholar]
- 23.Corbi A L, Kishimoto T K, Miller L J, Springer T A. J Biol Chem. 1988;263:12403–12411. [PubMed] [Google Scholar]
- 24.Stemmer W P C, Morris S K. BioTechniques. 1992;13:215–220. [PubMed] [Google Scholar]
- 25.Hibbs M L, Wardlaw A J, Stacker S A, Anderson D C, Lee A, Roberts T M, Springer T A. J Clin Invest. 1990;85:674–681. doi: 10.1172/JCI114491. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Aruffo A, Seed B. Proc Natl Acad Sci USA. 1987;84:8573–8577. doi: 10.1073/pnas.84.23.8573. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.English D, Anderson B R. J Immunol Methods. 1974;5:249–252. doi: 10.1016/0022-1759(74)90109-4. [DOI] [PubMed] [Google Scholar]
- 28.Diamond M S, Springer T A. J Cell Biol. 1993;120:545–556. doi: 10.1083/jcb.120.2.545. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Levitt M. J Mol Biol. 1992;226:507–533. doi: 10.1016/0022-2836(92)90964-l. [DOI] [PubMed] [Google Scholar]
- 30.Sali A, Blundell T L. J Mol Biol. 1993;234:779–815. doi: 10.1006/jmbi.1993.1626. [DOI] [PubMed] [Google Scholar]
- 31.Vriend G. J Mol Graph. 1990;8:52–56. doi: 10.1016/0263-7855(90)80070-v. [DOI] [PubMed] [Google Scholar]
- 32.Strynadka N C J, James M N G. Annu Rev Biochem. 1989;58:951–998. doi: 10.1146/annurev.bi.58.070189.004511. [DOI] [PubMed] [Google Scholar]
- 33.Vyas N K, Vyas M N, Quiocho F A. Nature (London) 1987;327:635–638. doi: 10.1038/327635a0. [DOI] [PubMed] [Google Scholar]
- 34.Wells J A. Proc Natl Acad Sci USA. 1996;93:1–6. doi: 10.1073/pnas.93.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Stanley P, Bates P A, Harvey J, Bennett R I, Hogg N. EMBO J. 1994;13:1790–1798. doi: 10.1002/j.1460-2075.1994.tb06447.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Bazzoni G, Shih D-T, Buck C A, Hemler M A. J Biol Chem. 1995;270:25570–25577. doi: 10.1074/jbc.270.43.25570. [DOI] [PubMed] [Google Scholar]
- 37.D’Souza S E, Ginsberg M H, Matsueda G R, Plow E F. Nature (London) 1991;350:66–68. doi: 10.1038/350066a0. [DOI] [PubMed] [Google Scholar]
- 38.Steiner B, Cousot D, Trzeciak A, Gillessen D, Hadvary P. J Biol Chem. 1989;264:13102–13108. [PubMed] [Google Scholar]
- 39.Gulino D, Boudignon C, Zhang L, Concord E, Rabiet M-J, Marguerie G. J Biol Chem. 1992;267:1001–1007. [PubMed] [Google Scholar]
- 40.Falke J J, Drake S K, Hazard A L, Peersen O B. Q Rev Biophys. 1994;27:219–290. doi: 10.1017/s0033583500003012. [DOI] [PubMed] [Google Scholar]
- 41.Irie A, Kamata T, Takada Y. Proc Natl Acad Sci USA. 1997;94:7198–7203. doi: 10.1073/pnas.94.14.7198. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Huang C, Springer T A. Proc Natl Acad Sci USA. 1997;94:3162–3167. doi: 10.1073/pnas.94.7.3162. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Davies D R, Padlan E A, Sheriff S. Annu Rev Biochem. 1990;59:439–473. doi: 10.1146/annurev.bi.59.070190.002255. [DOI] [PubMed] [Google Scholar]
- 44.Davies D R, Cohen G H. Proc Natl Acad Sci USA. 1996;93:7–12. doi: 10.1073/pnas.93.1.7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Kawasaki H, Kretsinger R H. Protein Profile. 1994;1:343–517. [PubMed] [Google Scholar]